Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 5Completed 2Withdrawn 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Advanced Solid Tumor 6Carcinoma, Hepatocellular 4Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Neoplasms 2Nasopharyngeal Carcinoma 2Advanced Solid Tumors 2Advanced Lung Cancer 2Urinary Bladder Neoplasms 1Treatment-naive Advanced Non-small Cell Lung Cancer 1Sarcoma 1Recurrence 1Mouth Neoplasms 1Melanoma 1Lymphoma 1Locally Advanced or Metastatic Solid Tumors 1Locally Advanced Rectal Cancer 1Liver Neoplasms 1Liver Diseases 1Kidney Neoplasms 1High-Risk Resectable NSCLC 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Chondrosarcoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Brain Neoplasms 1Anus Neoplasms 1Anal Canal Carcinoma 1Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Neoplasms × toripalimab × Clear all
NCT04374877 2025-11-10

Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Coherus Oncology, Inc.

Phase 1 Completed
145 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Neoplasms

NCT04991506 2025-06-23

A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors

Elpiscience Biopharma, Ltd.

Phase 1 Completed
30 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡